Development of Mucoadhesive Sustained Release Floating Tablets of Silymarin using Natural Polymer for Improved Anti-Parkinson Efficacy
Objective: The objective of the present investigation was to develop Mucoadhesive sustained release floating tablets of Silymarin using natural polymers (Coccinia grandis and Rumex vasicarious)…Clinical Management of Incipient Wearing-off with the 19-Items Wearing off Questionnaire (WOQ-19)
Objective: To evaluate the use of the 19-items Wearing off Questionnaire (WOQ-19) to detect fluctuations in patients with non-advanced Parkinson's disease (PD) and to evaluate…Efficacy and safety of zonisamide in patients with dementia with Lewy bodies with parkinsonism: pooled analysis of phase 2 and 3 trials
Objective: To characterize the efficacy and safety of zonisamide (ZNS) in patients with dementia with Lewy bodies (DLB) with parkinsonism, a pooled analysis of two…GLYCOPAR – A randomized, placebo-controlled, 2-arm parallel-group superiority phase II study of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease
Objective: To assess the 3-month efficacy and safety of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease. Background: A systematic review reported that sialorrhea affects approximately…Movement Disorders Patients in Long-Term Care: Protecting Access to Appropriate Treatment
Objective: To better understand the impact of gradual dose reduction (GDR) on patients with movement disorders living in long-term care facilities (LCTFs). Background: More than…Effects of zonisamide on parkinsonism in patients with dementia with Lewy bodies by severity of cognitive dysfunction and BPSD: subgroup analysis of pooled data from two trials
Objective: To characterize the efficacy and safety of zonisamide (ZNS) in patients with dementia with Lewy bodies (DLB) with parkinsonism, we performed subgroup analysis by…Continuous circadian intracerebroventricular administration of anaerobic dopamine: A new therapeutic concept for Parkinson’s disease?
Objective: We aim to overcome these challenges by demonstrating that continuous i.c.v. of Anaerobic-dopamine (A-dopamine,Patent #WO2015173258 A1) close to the striatum is a feasible and…Effect of gastrointestinal surgery on the pharmacokinetics of levodopa in Parkinson’s disease
Objective: The aim of this study is to evaluate the pharmacokinetics of levodopa in patients with Parkinson’s disease (PD) who underwent gastrointestinal surgery. Background: Levodopa…Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials
Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients, the ability of opicapone (OPC) to act as levodopa-sparing agent. Background: OPC, a once-daily COMT inhibitor,…Multi-kinase Abelson (c-Abl) and Discoidin Domain Receptors (DDR1/2) inhibitors, Nilotinib, alters CSF soluble TREM2 (sTREM2) in individuals with Parkinson’s Disease
Objective: Our objective was to examine the effects of broad-based tyrosine kinase inhibition in cerebrospinal fluid biomarkers. Background: Nilotinib is a broad-based tyrosine kinase inhibitor…
- « Previous Page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- …
- 34
- Next Page »